Zynex, Inc. (OTCBB:ZYXI),
a provider of pain management systems and electrotherapy products for
medical patients with functional disability, announces an increase in
its orders of 154% for September of 2008 compared to the same month last
year.
Thomas Sandgaard, CEO, commented, "We are pleased to see our orders
continue to increase and post another record month."
Zynex received 2,643 orders in September 2008 versus 1,042 orders twelve
months ago and 2,252 orders in August 2008. Zynex has not yet finalized
its results for the third quarter of 2008, including the impact of
increased orders. Zynex will state these results in the Form 10-Q for
the quarter.
About Zynex, Inc.
Zynex (founded in 1996) engineers, manufactures, markets and sells its
own design of electrotherapy medical devices in two distinct markets:
standard digital electrotherapy products for pain relief and pain
management; and the NeuroMoveTM for stroke and
spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully
developed, FDA-cleared, commercially sold, and have been developed to
uphold the Company's mission of improving the quality of life for
patients suffering from impaired mobility due to stroke, spinal cord
injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are
subject to numerous risks and uncertainties. Actual results may vary
significantly from the results expressed or implied in such statements.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the need to
obtain external capital in order to grow our business, larger
competitors with greater financial resources, the need to keep pace with
technological changes, our dependence on the reimbursement from
insurance companies for products sold or rented to our customers, our
dependence on third party manufacturers to produce our goods on time and
to our specifications, the acceptance of our products by hospitals and
clinicians, implementation of our sales strategy including a strong
direct sales force and other risks described in our 10-KSB Report for
the year ended December 31, 2007.
Zynex, Inc.
Thomas Sandgaard, CEO, 303-703-4906
www.zynexmed.com
